Unibest

Pharmaceutical intermediates

Acalabrutinib Intermediates

6 pharmaceutical intermediates for Acalabrutinib. Indication: Mantle cell lymphoma; chronic lymphocytic leukemia; lymphocytic leukemia.

提交项目All intermediates

About Acalabrutinib

Originator
AstraZeneca; Acerta Pharma Ltd
Indication
Mantle cell lymphoma; chronic lymphocytic leukemia; lymphocytic leukemia
Approved Date
10/31/2017
DS/DP
07/11/2031

Available intermediates

6 intermediates currently listed for Acalabrutinib. Request specifications, documentation or a quotation for any item below.

Acalabrutinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Butynoic Acid590-93-2//
2-Butynoyl Chloride39753-54-3//
3-Chloro-2-pyrazinemethanamine hydrochloride939412-86-9//
(S)-Benzyl 2-(8-amino-1-bromoimidazo[1,5 -a]pyrazin-3- yl)pyrrolidine-1-carboxylate1420478-88-1//
[4-[(Pyridin-2-yl)carbamoyl]phenyl]boronic acid850568-25-1//
4-[8-Amino-3-(2S)-2-pyrrolidinylimidazo[1,5 -a]pyrazin-1-yl]-N-2- pyridinylbenzamide1420478-90-5//

Other programs under A

AbemaciclibAbrocitinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidolAlogliptin/ Trelagliptin

Building toward Acalabrutinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →